BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

Lynk Pharmaceuticals Completes Phase III Enrolment for Zemprocitinib in Ankylosing Spondylitis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

July 16, 2026 | News

Kelun-Biotech’s Sac-TMT–Keytruda Combination Outperforms Standard First-Line Therapy in Phase III Lung Cancer Trial

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-L...

July 16, 2026 | News

Delonix Bioworks Doses First Participant in China Phase 1 Trial of Next-Generation MenB Vaccine DX-104

Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, announced that the first participant has bee...

July 15, 2026 | News

Leads Biolabs' Opamtistomig Receives China's Priority Review for Advanced Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Op...

July 14, 2026 | News

Insilico Medicine and China Medical System Expand AI Drug Discovery Alliance with RMB 1.2 Billion CNS Collaboration

Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Med...

July 14, 2026 | News

WuXi Biologics' Hebei Facility Clears US FDA Pre-License Inspection for Commercial Manufacturing

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance ma...

July 13, 2026 | News

China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the biologics license application (BLA) for Op...

July 13, 2026 | News

Lynk Pharmaceuticals Doses First Patient in Phase II Trial of Novel Vitiligo Therapy

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

July 10, 2026 | News

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

Everest Medicines Closes Global Civorebrutinib Licensing Deal Worth Up to $1.14 Billion

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

July 09, 2026 | News

Insilico Medicine Advances AI-Discovered IPF Drug Rentosertib into Phase III Trial

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-...

July 09, 2026 | News

LG Chem and OTR Therapeutics Partner to Advance China-Sourced Oncology Assets Globally

OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today an...

July 09, 2026 | News

World's First International Patient Begins Satri-cel Treatment at Jiahui International Cancer Center

Jiahui International Cancer Center (JICC) has welcomed the world's first international patient to begin treatment with Satri-cel, the world's first approve...

July 08, 2026 | News

Stay Connected